CrossRef Text and Data Mining
Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.
A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Byung Chul You, Young Seok Kim, Hun il Kim, Se Hun Kim, Seung Sik Park, Yu Ri Seo, Sang Gyune Kim, Se Whan Lee, Hong Soo Kim, Soung Won Jeong, Jae Young Jang, Boo Sung Kim
Clin Mol Hepatol. 2012;18(3):272-278.   Published online 2012 September 25    DOI: https://doi.org/10.3350/cmh.2012.18.3.272

Excel Download

A reduced dose of ribavirin does not influence the virologic response during pegylated interferon alpha-2b and ribavirin combination therapy in patients with genotype 1 chronic hepatitis C
Clinical and Molecular Hepatology. 2012;18(3):272   Crossref logo
Link1 Link2 Link3

Tu1499 – Vitamin D Deficiency and Sustained Virologic Response on Antiviral Therapy with Pegylated Interferon Alpha 2 and Ribavirin in Patients with Chronic Hepatitis C, Genotype-1
Gastroenterology. 2019;156(6):S-1344   Crossref logo
Link1 Link2

Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)
Gastroenterology. 2001;120(5):A568-A568   Crossref logo
Link1 Link2

Impact of early viral kinetics on pegylated interferon alpha 2b plus ribavirin therapy in Japanese patients with genotype 2 chronic hepatitis C
Journal of Viral Hepatitis. 2009;16(5):346-351   Crossref logo
Link1 Link2

Pegylated interferon alpha 2B (peg IFN)_plus ribavirin (R) for the treatment of chronic hepatitis c: optimization fo ribavirin dose
Journal of Hepatology. 2001;34:237-257   Crossref logo
Link1 Link2

P.275 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients non-responders to alpha interferferon plus ribavirin
Journal of Clinical Virology. 2006;36:S147   Crossref logo
Link1 Link2

P.276 Influence of genotype, viral load and fibrosis on the sustained virologic response rate to pegylated interferon alpha-2a plus ribavirin, with or without amantadine, in chronic hepatitis C patients relapsers to alpha interferferon plus ribavirin
Journal of Clinical Virology. 2006;36:S147-S148   Crossref logo
Link1 Link2

Re-treatment virologic response in chronic hepatitis C virologic non-responders (NR) and responder-relapsers (NR) to interferon (IFN) monotherapy: IFN α-2b induction followed by combination ribavirin/interferon α-2b vs combination ribavirin/interferon α-2b (780 MIU/52 weeks rebetron therapy)
Gastroenterology. 2001;120(5):A568   Crossref logo
Link1 Link2

Combination treatment of alpha interferon-2b (alpha IFN) and ribavirin in chronic hrpatitis C genotype 4 patients resistant to interferon therapy
Hepatology. 1995;22(4):A152   Crossref logo
Link1 Link2

W1016 Efficacy and Safety of Erythropoietin-Alfa On NaïVe Patients with Chronic Hepatitis C and Genotype 1 Receiving Combination Therapy with Pegylated Interferon-Alfa 2b and Ribavirin
Gastroenterology. 2008;134(4):A-832-A-833   Crossref logo
Link1 Link2

This metadata service is kindly provided by CrossRef from May 29, 2014. Clin Mol Hepatol has participated in CrossRef Text and Data Mining service since March 1, 2015.